Prevalence of obesity in students with specific learning disorder in a metropolitan city of India

Background: Obesity is common in urban school children. Learning disability (LD) prevalence is also growing, primarily in cities. Objective: The objective of this study is to find the prevalence of obesity in students with specific LD (SLD). Materials and Methods: This observational cross-sectional study carried out at a tertiary care center attached to a medical college in Maharashtra, after obtaining permission from the institutional ethics committee. Consecutive 150 students with SLD between the ages of 8 and 18 years were studied over 18 months. Obesity was classified as per body mass index. Descriptive statistics and subgroup analysis were done by unpaired t-test. Results: Prevalence of obesity in students with SLD was 22.7% without genderpredisposition and family history correlation. Of total students with SLD, 44 (29.3%) had attention-deficit hyperactivity disorder (ADHD) without any association with the obesity. Conclusions: Family history, ADHD, gender, other medical conditions, and drug history have no correlation with regard to obesity in SLD. There is a further requirement of research with large population control size

The Hiyama Cross-Coupling Reaction: New Discoveries

In this account recent developments in the Hiyama cross-coupling reaction from 2010 up today are presented. The most important methodology involves formation of biaryl systems by using aryl bromides or iodides and aryl trialkoxy silanes: other variants are far less studied. The most useful procedures are collected paying special attention to the synthetic application of this methodology in synthetic organic chemistry.We thank the continuous financial support from our Ministerio de Ciencia e Innovación (MCINN; projects CTQ2007-62771/BQU, CTQ2010-20387, CONSOLIDER INGENIO 210-CDS2007-00006, CTQ2011-24151, CTQ2011-24165), the Ministerio de Economía y Competitividad (MINECO; projects CTQ2013-43446-P, CTQ2014-51912-REDC, CTQ2014-53695-P), FEDER, the Generalitat Valenciana (PROMETEO 2009/039, PROMETEOII/2014/017) and the University of Alicante

Systemic Anticancer Therapy and Thromboembolic Outcomes in Hospitalized Patients With Cancer and COVID-19

IMPORTANCE: Systematic data on the association between anticancer therapies and thromboembolic events (TEEs) in patients with COVID-19 are lacking. OBJECTIVE: To assess the association between anticancer therapy exposure within 3 months prior to COVID-19 and TEEs following COVID-19 diagnosis in patients with cancer. DESIGN, SETTING, AND PARTICIPANTS: This registry-based retrospective cohort study included patients who were hospitalized and had active cancer and laboratory-confirmed SARS-CoV-2 infection. Data were accrued from March 2020 to December 2021 and analyzed from December 2021 to October 2022. EXPOSURE: Treatments of interest (TOIs) (endocrine therapy, vascular endothelial growth factor inhibitors/tyrosine kinase inhibitors [VEGFis/TKIs], immunomodulators [IMiDs], immune checkpoint inhibitors [ICIs], chemotherapy) vs reference (no systemic therapy) in 3 months prior to COVID-19. MAIN OUTCOMES AND MEASURES: Main outcomes were (1) venous thromboembolism (VTE) and (2) arterial thromboembolism (ATE). Secondary outcome was severity of COVID-19 (rates of intensive care unit admission, mechanical ventilation, 30-day all-cause mortality following TEEs in TOI vs reference group) at 30-day follow-up. RESULTS: Of 4988 hospitalized patients with cancer (median [IQR] age, 69 [59-78] years; 2608 [52%] male), 1869 had received 1 or more TOIs. Incidence of VTE was higher in all TOI groups: endocrine therapy, 7%; VEGFis/TKIs, 10%; IMiDs, 8%; ICIs, 12%; and chemotherapy, 10%, compared with patients not receiving systemic therapies (6%). In multivariable log-binomial regression analyses, relative risk of VTE (adjusted risk ratio [aRR], 1.33; 95% CI, 1.04-1.69) but not ATE (aRR, 0.81; 95% CI, 0.56-1.16) was significantly higher in those exposed to all TOIs pooled together vs those with no exposure. Among individual drugs, ICIs were significantly associated with VTE (aRR, 1.45; 95% CI, 1.01-2.07). Also noted were significant associations between VTE and active and progressing cancer (aRR, 1.43; 95% CI, 1.01-2.03), history of VTE (aRR, 3.10; 95% CI, 2.38-4.04), and high-risk site of cancer (aRR, 1.42; 95% CI, 1.14-1.75). Black patients had a higher risk of TEEs (aRR, 1.24; 95% CI, 1.03-1.50) than White patients. Patients with TEEs had high intensive care unit admission (46%) and mechanical ventilation (31%) rates. Relative risk of death in patients with TEEs was higher in those exposed to TOIs vs not (aRR, 1.12; 95% CI, 0.91-1.38) and was significantly associated with poor performance status (aRR, 1.77; 95% CI, 1.30-2.40) and active/progressing cancer (aRR, 1.55; 95% CI, 1.13-2.13). CONCLUSIONS AND RELEVANCE: In this cohort study, relative risk of developing VTE was high among patients receiving TOIs and varied by the type of therapy, underlying risk factors, and demographics, such as race and ethnicity. These findings highlight the need for close monitoring and perhaps personalized thromboprophylaxis to prevent morbidity and mortality associated with COVID-19-related thromboembolism in patients with cancer

Scholarly publishing depends on peer reviewers

The peer-review crisis is posing a risk to the scholarly peer-reviewed journal system. Journals have to ask many potential peer reviewers to obtain a minimum acceptable number of peers accepting reviewing a manuscript. Several solutions have been suggested to overcome this shortage. From reimbursing for the job, to eliminating pre-publication reviews, one cannot predict which is more dangerous for the future of scholarly publishing. And, why not acknowledging their contribution to the final version of the article published? PubMed created two categories of contributors: authors [AU] and collaborators [IR]. Why not a third category for the peer-reviewer?Scopu

CAR T-cell therapy: is it prime time in myeloma?

Chimeric antigen receptor (CAR) T cells have shown promising activity in hematological malignancies and are being studied for the treatment of multiple myeloma, as well. B-cell maturation antigen, which is widely and almost exclusively expressed on plasma cells and B cells, is a promising target. Other targets being evaluated include CD19, CD38, CD138, signaling lymphocyte activation molecule or CS1, light chain, GPRC5D, and NKG2D. Early clinical studies have shown promising response rates in heavily pretreated patients, but relapses have occurred. Cytokine release syndrome and neurotoxicity have been observed in the majority of patients but are mostly grades 1 and 2. Relapse may be mediated by antigen escape and the limited persistence of CAR T cells. CAR T-cell constructs that target multiple antigens/epitopes or constructs with longer persistence due to a higher proportion of memory phenotype T cells may decrease the rates of relapse. Allogeneic CAR T cells that offer "off-the-shelf" options are also being developed. The challenges in integrating CAR T cells in myeloma therapy include disease relapse, adverse effects, cost, and identifying the right patient population. Longer-term data on efficacy and toxicity are needed before CAR T cells are ready for prime time in myeloma

CAR T-cell therapy: is it prime time in myeloma?

Chimeric antigen receptor (CAR) T cells have shown promising activity in hematological malignancies and are being studied for the treatment of multiple myeloma, as well. B-cell maturation antigen, which is widely and almost exclusively expressed on plasma cells and B cells, is a promising target. Other targets being evaluated include CD19, CD38, CD138, signaling lymphocyte activation molecule or CS1, light chain, GPRC5D, and NKG2D. Early clinical studies have shown promising response rates in heavily pretreated patients, but relapses have occurred. Cytokine release syndrome and neurotoxicity have been observed in the majority of patients but are mostly grades 1 and 2. Relapse may be mediated by antigen escape and the limited persistence of CAR T cells. CAR T-cell constructs that target multiple antigens/epitopes or constructs with longer persistence due to a higher proportion of memory phenotype T cells may decrease the rates of relapse. Allogeneic CAR T cells that offer "off-the-shelf" options are also being developed. The challenges in integrating CAR T cells in myeloma therapy include disease relapse, adverse effects, cost, and identifying the right patient population. Longer-term data on efficacy and toxicity are needed before CAR T cells are ready for prime time in myeloma

Comparative study of obstetric outcome in overweight and obese pregnant women

Background: The World Health Organization has described obesity as one of today's most neglected public health problems, affecting every region of the globe. The objective of the present study was to compare obstetric outcome in overweight and obese pregnant women.Methods: A prospective observational study was conducted in obstetrics and gynecology department in KEM hospital, Mumbai between 2014- 2015 to study the effects of maternal BMI on maternal and perinatal outcome and to compare the obstetric outcome (maternal and perinatal) between overweight and obese mother. All antenatal patients fulfilling inclusion criteria were divided in two groups, overweight and obese based on BMI <30 kg/m2 and >30 kg/m2 respectively. Distribution of maternal risk factors like gestational hypertension and preeclampsia, gestational diabetes mellitus, unfavourable obstetric history specially in previous pregnancy like miscarriages, and instances of fetal demise, history of previous caesarean section and perinatal outcome were studied.Results: Maternal personal characteristics like increased age and low education level were related to high BMI and antenatal complications like gestational diabetes, gestational hypertension, malpresentation, preterm labor, incidences of assisted vaginal delivery and rate of caesarean section and perinatal complications were higher in obese group.Conclusions: The study concluded that obesity has adverse effects on pregnancy outcome on both mothers and their infants. Increased age and low education status in relation with high BMI showed adverse pregnancy outcome. Stronger association seen between family history of obesity and diabetes and increased BMI. This study revealed that GDM, Gestational hypertension and malpresentations found commoner in obese mothers than overweight mothers